Prakash Sampath
Tanzania
Research Article
Irinotecan and BCNU-Impregnated Wafers Used in Combination, for the Treatment of Patients with Recurrent Glioblastoma Multiforme
Author(s): Sheri Dewan, Edward Stopa, Lloyd Alderson and Prakash Sampath
Sheri Dewan, Edward Stopa, Lloyd Alderson and Prakash Sampath
Introduction: This retrospective study examines the toxicity of the combination of intravenous irinotecan, (CPT-11; Camptosar®; Pharmacia & Upjohn, Kalamazoo, Mich.) and BCNU (1,3-bis(2-chloroethyl)-1-nitrosurea) impregnated wafers (Gliadel®) following implantation at the time of tumor recurrence in patients with glioblastoma multiforme (GBM). Method: Ten patients with recurrent GBM were examined in this study. The inclusion criteria were histologically confirmed GBM, Karnofsky’s Performance Scale (KPS) greater than or equal to 60, and a single focus of recurrent tumor. All patients underwent resection of their tumor at the time of first recurrence with placement of BCNU wafers. Postoperatively, patients were treated with irinotecan. One cycle constituted of 125 mg/m2 once weekly for 4 weeks followed by a 2-week rest. The patients we.. View More»
DOI:
10.4172/2157-2518.1000101